Hong Kong Winhealth Pharma Group (hereinafter referred to as "Winhealth Pharma") is a China-based, global innovative biomedical company founded in 2006, providing novel breakthrough therapies to patients with rare diseases and other unmet medical needs.
Dr. Meng Ling, a strategic medical and clinical expert in the pharmaceutical industry who has international perspective and experience, a leader in medical field who has a successful record of New Drug Application (NDA), formally joined Winhealth Pharma as Chief Medical Officer on August 11, 2021.
"Dr. Meng Ling will be one of the main directors for the establishment of the innovative drug product development pipeline of Winhealth Pharma, responsible for the clinical development of the company’s products, designing positioning of indications, the formulation and implementation of clinical development strategies and clinical pathway, as well as communication with experts from clinical research institutions, and supervision of external clinical service organizations, and assisting the group’s marketing application, etc.” "Dr. Meng will build an excellent Clinical Medicine Department for Winhealth Pharma, establish and improve the clinical development and medical capabilities of Winhealth Pharma. We are looking forward that Dr. Meng will be a member of us, to jointly build the grand blueprint for the healthcare undertaking with Winhealth Pharma.” Mr. Wang Wei, the founder, Chairman and CEO of Winhealth Pharma said.
Dr. Meng Ling was graduated from the Air Force Medical University of PLA (the Fourth Military Medical University) in Xi’an, and successively obtained a Master's Degree and a Doctoral Degree in Cardiovascular Diseases from the Chinese PLA Medical School (Chinese PLA General Hospital, Beijing 301 Hospital). In 2005, she was selected by the China Scholarship Council to be a visiting scholar at the Institut national de la santé et de la recherche médicale (INSERM) and Georges Pompidou European Union Hospital in Paris, and studied for the clinical application study of cell therapy under the tutelage of Dr. MENASCHE, a well-known cardiologist.
Dr. Meng has more than 25 years of experience in the field of thrombosis, haemorrhage, coagulation (including hemophilia) and cardiovascular diseases. She served as the Deputy Director of Global Medical Affairs in the field of cardiovascular therapy at Bayer's headquarters in Berlin, Germany before joining Winhealth Pharma, making her possess extensive clinical experience and clinical research and development.
About Winhealth Pharma
Hong Kong Winhealth Pharma Group is a China-based, global innovative biomedical company founded in 2006, providing novel breakthrough therapies to patients with rare diseases and other unmet medical needs. The Group has established long-term strategic partnership with dozens of world-leading biotechnology companies, including Immedica, Roche, Pfizer, Kyowa Kirin, Shionogi, Cumberland Pharmaceutical, and Daiichi-Sankyo. It has built a unique, balanced and diversified portfolio with numerous innovative rare disease and specialty products at commercial and late clinical stages, some with blockbuster potential, and will continuously look to bring in more innovative therapies from the globe.